Shanghai Sanyou Medical (SHA:688085) established a biotechnology joint venture in partnership with South Korean counterpart CGBio, according to a Shanghai Stock Exchange filing on Friday.
The venture, Litian (Taicang) Biotechnology, has a registered capital of 60 million yuan and will develop regenerative medicine, such as innovative cellular biomaterials.
The Chinese orthopedic products manufacturer invested 39.6 million yuan, owning 66% of the venture, and CGBio injected 20.4 million yuan, holding the venture's remaining 34%.
Sanyou's shares closed less than 2% higher.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。